摘要
目的:探讨替格瑞洛对冠心病(CHD)患者经皮冠状动脉介入治疗(PCI)术后心肌酶谱与凝血指标的影响.方法:选取2021年8月至2023年10月本院收治的101例行PCI治疗的CHD患者为研究对象.根据治疗方法,将其分为观察组(n=51,给予替格瑞洛治疗)和对照组(n=50,给予氯吡格雷治疗).比较两组患者心肌酶谱指标[心肌肌钙蛋白I(cTnI)、乳酸脱氢酶(LDH)、肌酸激酶同工酶-MB(CK-MB)],凝血功能指标[凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)],以及心血管不良事件和出血事件的发生率.结果:治疗3个月后,两组患者cTnI、LDH、CK-MB水平均较治疗前降低,且观察组患者低于对照组,差异均有统计学意义(P<0.05).两组患者TT、PT、APTT均延长,且观察组患者长于对照组,差异具有统计学意义(P<0.05).观察组患者心血管不良事件及出血事件发生率均低于对照组,差异具有统计学意义(P<0.05).结论:替格瑞洛可有效改善CHD患者PCI术后心肌酶谱与凝血指标,并降低心血管不良事件与出血事件的发生风险.
Objective:To explore the effect of ticagrelor on myocardial enzyme profiles and coagulation indices in patients with coronary heart disease(CHD)after percutaneous coronary intervention(PCI).Methods:A total of 101 CHD patients who underwent PCI at our hospital from August 2021 to October 2023 were enrolled as study subjects.According to the treatment method,they were divided into observation group(n=51,treated with ticagrelor)and control group(n=50,treated with clopidogrel).The myocardial enzyme profiles[cardiac troponin I(cTnI),lactate dehydrogenase(LDH),creatine kinase-MB(CK-MB)],coagulation function indices[thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT)],as well as the incidence rates of adverse cardiovascular events and bleeding events were compared between the two groups.Results:After 3 months of treatment,the levels of cTnI,LDH,and CK-MB decreased in both groups compared to pre-treatment levels,with observation group showing lower levels than those of control group,and the differences were statistically significant(P<0.05).TT,PT,and APTT were prolonged in both groups,and these times were longer in observation group than those in control group,and the differences were statistically significant(P<0.05).The incidence rates of adverse cardiovascular events and bleeding events were lower in observation group than those in control group,and the differences were statistically significant(P<0.05).Conclusion:Ticagrelor can effectively improve myocardial enzyme profiles and coagulation indices,and reduce the risk of adverse cardiovascular events and bleeding events in CHD patients after PCI.
作者
吕海科
乔印涛
朱洪佳
LV Haike;QIAO Yintao;ZHU Hongjia(Department of Cardiovascular Medicine,Fangcheng County People's Hospital,Nanyang 473299,China)
出处
《四川解剖学杂志》
2025年第5期41-43,共3页
Sichuan Journal of Anatomy
关键词
心肌酶谱
凝血指标
替格瑞洛
冠心病
Myocardial enzyme profiles
Coagulation indices
Ticagrelor
Coronary heart disease
